Benign Essential Blepharospasm Medication

1. Titi-Lartey OA, Patel BC. Benign Essential Blepharospasm. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].

2. Houser M, Waltz T. Meige syndrome and pallidal deep brain stimulation. Mov Disord. 2005 Sep. 20(9):1203-5. [QxMD MEDLINE Link].

3. Etgen T, Muhlau M, Gaser C. Bilateral putaminal grey-matter increase in primary blepharospasm. J Neurol Neurosurg Psychiatry. 2006 May 11. [QxMD MEDLINE Link].

4. Fahn S. Blepharospasm: A focal dystonia. In: Bosniak S, ed. Advances in Ophthalmic Plastic and Reconstructive Surgery. Vol 4. Elsevier Science. 1985:87-91.

5. Jankovic J. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988. 49:103-16. [QxMD MEDLINE Link].

6. Jankovic JJ. Clinical features, differential diagnosis, and pathogenesis of blepharospasm and cranial-cervical dystonia. In: Bosniak S, ed. Advances in Ophthalmic Plastic and Reconstructive Surgery. Vol 4. Elsevier Science. 1985:67-82.

7. McCann JD, Gauthier M, Morschbacher R, et al. A novel mechanism for benign essential blepharospasm. Ophthal Plast Reconstr Surg. 1999 Nov. 15(6):384-9. [QxMD MEDLINE Link].

8. Horie C, Suzuki Y, Kiyosawa M, Mochizuki M, Wakakura M, Oda K, et al. Decreased dopamine D(2) receptor binding in essential blepharospasm. Acta Neurol Scand. 2008 Jun 5. [QxMD MEDLINE Link].

9. Morrison DA, Mellington FB, Hamada S. Schwartz-Jampel syndrome: surgical management of the myotonia-induced blepharospasm and acquired ptosis after failure with botulinum toxin A injections. Ophthal Plast Reconstr Surg. 2006 Jan-Feb. 22(1):57-9. [QxMD MEDLINE Link].

10. Quartarone A, Sant'Angelo A, Battaglia F. Enhanced long-term potentiation-like plasticity of the trigeminal blink reflex circuit in blepharospasm. J Neurosci. 2006 Jan 11. 26(2):716-21. [QxMD MEDLINE Link].

11. Defazio G, Hallett M, Jinnah HA, Conte A, Berardelli A. Blepharospasm 40 years later. Mov Disord. 2017 Apr. 32 (4):498-509. [QxMD MEDLINE Link].

12. Peterson DA, Sejnowski TJ. A Dynamic Circuit Hypothesis for the Pathogenesis of Blepharospasm. Front Comput Neurosci. 2017. 11:11. [QxMD MEDLINE Link].

13. Fayers T, Shaw SR, Hau SC, Ezra DG. Changes in corneal aesthesiometry and the sub-basal nerve plexus in benign essential blepharospasm. Br J Ophthalmol. 2015 Apr 22. [QxMD MEDLINE Link].

14. Hall TA, McGwin G, Searcey K. Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol. 2006 Jan. 124(1):116-9. [QxMD MEDLINE Link].

15. Hall TA, McGwin G, Searcey K. Benign essential blepharospasm: risk factors with reference to hemifacial spasm. J Neuroophthalmol. 2005 Dec. 25(4):280-5. [QxMD MEDLINE Link].

16. Munhoz RP, Teive HA, Della Coletta MV. Frequency of obsessive and compulsive symptoms in patients with blepharospasm and hemifacial spasm. Arq Neuropsiquiatr. 2005 Jun. 63(2A):213-6. [QxMD MEDLINE Link].

17. Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol. 1984 Apr. 16(4):371-6. [QxMD MEDLINE Link].

18. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Experiment Ophthalmol. 2014 Apr. 42 (3):254-61. [QxMD MEDLINE Link].

19. Berardelli I, Ferrazzano G, Belvisi D, Baione V, Fabbrini G, Innamorati M, et al. Suicidal ideation, hopelessness, and affective temperament in patients with blepharospasm. Int J Psychiatry Clin Pract. 2021 Nov. 25 (4):344-349. [QxMD MEDLINE Link].

20. Bentivoglio AR, Daniele A, Albanese A. Analysis of blink rate in patients with blepharospasm. Mov Disord. 2006 Apr 18. [QxMD MEDLINE Link].

21. Henderson JW. Essential blepharospasm. Trans Am Ophthalmol Soc. 1956. 54:453-520.

22. Malinovsky V. Benign essential blepharospasm. J Am Optom Assoc. 1987 Aug. 58(8):646-51. [QxMD MEDLINE Link].

23. Moon NJ, Lee HI, Kim JC. The changes in corneal astigmatism after botulinum toxin-a injection in patients with blepharospasm. J Korean Med Sci. 2006 Feb. 21(1):131-5. [QxMD MEDLINE Link].

24. Ronald W. Essential blepharospasm: An often missed diagnosis. In: Bosniak S, ed. Advances in Ophthalmic Plastic and Reconstructive Surgery. Vol 4. Elsevier Science. 1985:93-95.

25. Martino D, Defazio G, Alessio G. Relationship between eye symptoms and blepharospasm: a multicenter case-control study. Mov Disord. 2005 Dec. 20(12):1564-70. [QxMD MEDLINE Link].

26. Ben Simon GJ, McCann JD. Benign essential blepharospasm. Int Ophthalmol Clin. 2005. 45(3):49-75. [QxMD MEDLINE Link].

27. Defazio G, Martino D, Aniello MS. A family study on primary blepharospasm. J Neurol Neurosurg Psychiatry. 2006 Feb. 77(2):252-4. [QxMD MEDLINE Link].

28. Srivastava T, Goyal V, Singh S. Pallido-pyramidal syndrome with blepharospasm and good response to levodopa. J Neurol. 2005 Dec. 252(12):1537-8. [QxMD MEDLINE Link].

29. Weiss EM, Hershey T, Karimi M. Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord. 2006 May 3. [QxMD MEDLINE Link].

30. Defazio G, Abbruzzese G, Aniello MS, et al. Environmental risk factors and clinical phenotype in familial and sporadic primary blepharospasm. Neurology. 2011 Aug 16. 77(7):631-7. [QxMD MEDLINE Link].

31. Wabbels B. Botulinum toxin therapy in congenital blepharospasm. Case Rep Ophthalmol. 2014 Sep-Dec. 5 (3):435-8. [QxMD MEDLINE Link].

32. Zhou B, Wang J, Huang Y, Yang Y, Gong Q, Zhou D. A resting state functional magnetic resonance imaging study of patients with benign essential blepharospasm. J Neuroophthalmol. 2013 Sep. 33(3):235-40. [QxMD MEDLINE Link].

33. Serefoglu Cabuk K, Tunc U, Ozturk Karabulut G, Fazil K, Karaagac Gunaydin Z, Asik Nacaroglu S, et al. Serum calcium, magnesium, phosphorus, and vitamin D in benign essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 2020 Jun. 258 (6):1293-1297. [QxMD MEDLINE Link].

34. DAS S, Sreedharan RP, Remadevi PS, Saji CV. Psychogenic Blepharospasm: A Diagnostic Dilemma. Shanghai Arch Psychiatry. 2016 Dec 25. 28 (6):346-348. [QxMD MEDLINE Link].

35. Asanuma K, Carbon-Correll M, Eidelberg D. Neuroimaging in human dystonia. J Med Invest. 2005 Nov. 52 Suppl:272-9. [QxMD MEDLINE Link].

36. Dresel C, Haslinger B, Castrop F. Silent event-related fMRI reveals deficient motor and enhanced somatosensory activation in orofacial dystonia. Brain. 2006 Jan. 129(Pt 1):36-46. [QxMD MEDLINE Link].

37. Herz NL, Yen MT. Modulation of sensory photophobia in essential blepharospasm with chromatic lenses. Ophthalmology. 2005 Dec. 112(12):2208-11. [QxMD MEDLINE Link].

38. Adams WH, Digre KB, Patel BC, Anderson RL, Warner JE, Katz BJ. The evaluation of light sensitivity in benign essential blepharospasm. Am J Ophthalmol. 2006 Jul. 142(1):82-87. [QxMD MEDLINE Link].

39. Blackburn MK, Lamb RD, Digre KB, Smith AG, Warner JE, McClane RW, et al. FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm. Ophthalmology. 2009 May. 116(5):997-1001. [QxMD MEDLINE Link]. [Full Text].

40. Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008 Oct 14. 71(16):1275-82. [QxMD MEDLINE Link].

41. Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg. 1998 Sep. 14(5):305-17. [QxMD MEDLINE Link].

42. Bradley EA, Bradley D, Bartley GB. Evaluating health-related quality of life in ophthalmic disease: practical considerations. Arch Ophthalmol. 2006 Jan. 124(1):121-2. [QxMD MEDLINE Link].

43. Barnes MP, Best D, Kidd L. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences. Eur J Neurol. 2005 Dec. 12(12):947-55. [QxMD MEDLINE Link].

44. Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol. 2006 Feb. 13 Suppl 1:21-9. [QxMD MEDLINE Link].

45. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 2. Am J Health Syst Pharm. 2006 Feb 1. 63(3):225-32. [QxMD MEDLINE Link].

46. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 1. Am J Health Syst Pharm. 2006 Jan 15. 63(2):145-52. [QxMD MEDLINE Link].

47. Dutton JJ, White JJ, Richard MJ. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. Ophthal Plast Reconstr Surg. 2006 May-Jun. 22(3):173-7. [QxMD MEDLINE Link].

48. Seiff SR, Zwick OM. Botulinum toxin management of upper facial rhytidosis and blepharospasm. Otolaryngol Clin North Am. 2005 Oct. 38(5):887-902. [QxMD MEDLINE Link].

49. Silveira-Moriyama L, Goncalves LR, Chien HF. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq Neuropsiquiatr. 2005 Jun. 63(2A):221-4. [QxMD MEDLINE Link].

50. Truong D, Comella C, Fernandez HH, Ondo WG. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008. 14(5):407-14. [QxMD MEDLINE Link].

51. Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008. 115(4):585-91. [QxMD MEDLINE Link].

52. Roggenkamper P, Jost WH, Bihari K. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006 Mar. 113(3):303-12. [QxMD MEDLINE Link].

53. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10. 86 (19):1818-26. [QxMD MEDLINE Link].

54. Kocabeyoglu S, Sekeroglu HT, Mocan MC, Muz E, Irkec M, Sanac AS. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection. Eur J Ophthalmol. 2014 Nov-Dec. 24 (6):830-4. [QxMD MEDLINE Link].

55. Cote TR, Mohan AK, Polder JA. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005 Sep. 53(3):407-15. [QxMD MEDLINE Link].

56. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988 Jun. 51(6):767-72. [QxMD MEDLINE Link].

57. Ortisi E, Henderson HW, Bunce C. Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases. Eye. 2006 Mar 10. [QxMD MEDLINE Link].

58. Chundury RV, Couch SM, Holds JB. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm. Ophthal Plast Reconstr Surg. 2013 May-Jun. 29(3):205-7. [QxMD MEDLINE Link].

59. Saad J, Gourdeau A. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. J Neuroophthalmol. 2014 Sep. 34(3):233-6. [QxMD MEDLINE Link].

60. Lai HT, Chen AD, Lee SS, Lin YH, Lai CS. Myotomy In Situ for Essential Blepharospasm Refractory to Botulinum Toxin. Ann Plast Surg. 2020 Jan. 84 (1S Suppl 1):S74-S79. [QxMD MEDLINE Link].

61. Wabbels B, Fimmers R, Roggenkämper P. Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A-30 Years of Experience in a Tertiary Care Center. Toxins (Basel). 2022 Feb 7. 14 (2):[QxMD MEDLINE Link].

62. Yin B, Peng B, Luo Y, Fan S, Xiao T, Zou X, et al. Efficacy of Repetitive Transcranial Magnetic Stimulation Combined with Botulinum Toxin Type A for Benign Essential Blepharospasm Patients Accompanied by Anxiety and Depression. Neuropsychiatr Dis Treat. 2021. 17:2707-2711. [QxMD MEDLINE Link].

63. Garland PE, Patrinely JR, Anderson RL. Hemifacial spasm. Results of unilateral myectomy. Ophthalmology. 1987 Mar. 94(3):288-94. [QxMD MEDLINE Link].

64. Gillum WN, Anderson RL. Blepharospasm surgery. An anatomical approach. Arch Ophthalmol. 1981 Jun. 99(6):1056-62. [QxMD MEDLINE Link].

65. Grivet D, Robert PY, Thuret G. Assessment of blepharospasm surgery using an improved disability scale: study of 138 patients. Ophthal Plast Reconstr Surg. 2005 May. 21(3):230-4. [QxMD MEDLINE Link].

66. Patel BC. Surgical management of essential blepharospasm. Otolaryngol Clin North Am. 2005 Oct. 38(5):1075-98. [QxMD MEDLINE Link].

67. Patil B, Foss AJ. Upper lid orbicularis oculi muscle strip and sequential brow suspension with autologous fascia lata is beneficial for selected patients with essential blepharospasm. Eye. 2008 Oct 17. [QxMD MEDLINE Link].

68. Georgescu D, Vagefi MR, McMullan TF, McCann JD, Anderson RL. Upper eyelid myectomy in blepharospasm with associated apraxia of lid opening. Am J Ophthalmol. 2008 Mar. 145(3):541-547. [QxMD MEDLINE Link].

69. Kerty E, Eidal K. Apraxia of eyelid opening: Clinical features and therapy. Eur J Ophthalmol. 2006 Mar-Apr. 16(2):204-8. [QxMD MEDLINE Link].

70. Lopez Valdes E, Posada Rodriguez IJ, Bilbao-Calabuig R. Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases. Mov Disord. 2008 Apr 15. 23(5):773; author reply 773. [QxMD MEDLINE Link].

71. Jochim A, Meindl T, Huber C, Mantel T, Zwirner S, Castrop F, et al. Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice. J Neurol. 2020 Jan. 267 (1):267-275. [QxMD MEDLINE Link].

72. Karapantzou C, Dressler D, Rohrbach S, Laskawi R. Frontalis suspension surgery to treat patients with essential blepharospasm and apraxia of eyelid opening-technique and results. Head Face Med. 2014 Oct 22. 10:44. [QxMD MEDLINE Link].

73. Fine PG, Digre KB. A controlled trial of regional sympatholysis in the treatment of photo- oculodynia syndrome. J Neuroophthalmol. 1995 Jun. 15(2):90-4. [QxMD MEDLINE Link].

74. Minkin K, Gabrovski K, Dimova P, Tanova R, Penkov M, Todorov Y, et al. Bilateral pallidotomy for Meige syndrome. Acta Neurochir (Wien). 2017 Apr 19. [QxMD MEDLINE Link].

Robert H Graham, MD Consultant, Department of Ophthalmology, Mayo Clinic, Scottsdale, Arizona

Robert H Graham, MD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, Arizona Ophthalmological Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Edsel B Ing, MD, PhD, MBA, MEd, MPH, MA, FRCSC Professor, Department of Ophthalmology and Vision Sciences, Sunnybrook Hospital, University of Toronto Faculty of Medicine; Incoming Chair of Ophthalmology, University of Alberta Faculty of Medicine and Dentistry, Canada

Edsel B Ing, MD, PhD, MBA, MEd, MPH, MA, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Society of Ophthalmic Plastic and Reconstructive Surgery, Canadian Medical Association, Canadian Ophthalmological Society, Canadian Society of Oculoplastic Surgery, Chinese Canadian Medical Society, European Society of Ophthalmic Plastic and Reconstructive Surgery, North American Neuro-Ophthalmology Society, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada, Statistical Society of Canada

Disclosure: Nothing to disclose.

Ron W Pelton, MD, PhD Private Practice, Colorado Springs, Colorado

Ron W Pelton, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, AO Foundation, American Society of Ophthalmic Plastic and Reconstructive Surgery, Colorado Medical Society

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous coauthor, Stanley M Saulny, MD, to the development and writing of this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article